排序方式: 共有5条查询结果,搜索用时 15 毫秒
1
1.
Chinadol Wanitpongpun Eakkapol Utchariyaprasit Weerapat Owattanapanich Adisak Tantiworawit Ekarat Rattarittamrong Pimjai Niparuck Teeraya Puavilai Jakrawadee Julamanee Pirun Saelue Chantiya Chanswangphuwana Chantana Polprasert Chajchawan Nakhakes Wasithep Limvorapitak Nonglak Kanitsap Kannadit Prayongratana Chantrapa Sriswasdi 《Clinical Lymphoma, Myeloma & Leukemia》2021,21(7):e635-e643
BackgroundAcute myeloid leukemia (AML) is a common, challenging hematologic malignancy worldwide. Thai data on its characteristics and outcomes have never been systematically reported, to our knowledge. The objective of this study was to determine the clinical features and outcomes of Thai patients with AML.Patients and MethodsThis was a prospective observational study of nine academic hospitals. Patients with newly diagnosed AML were invited to register online.ResultsA total of 679 patients with AML were included. The presence of circulating peripheral blood blasts was correlated with a high white blood cell count. Acute promyelocytic leukemia (APL) had predominantly lower white blood cell counts and higher proportions without peripheral blood blasts compared with non-APL AML. Disseminated intravascular coagulation was commonly presented in APL (37.7%). Splenomegaly and normal platelet count were more frequently seen in patients with Philadelphia chromosome–positive AML. The median follow-up time for those who survived more than 1 year was 28.0 months. One-year overall survival rates for non-APL AML and APL were 31.9% and 88.2%, respectively; 2-year overall survival rates were 29.6% and 88.2%, respectively. Hematopoietic stem cell transplantation could improve survival in non-APL AML.ConclusionAPL should be considered despite absence of peripheral blood blast. This study demonstrates poor outcome of Thai AML and more research to improve outcomes are underway. Expanding access to hematopoietic stem cell transplantation should be considered in Thailand. 相似文献
2.
Daisuke Koyama Makoto Murata Ryo Hanajiri Tomohiro Akashi Shingo Okuno Sonoko Kamoshita Jakrawadee Julamanee Erina Takagi Kotaro Miyao Reona Sakemura Tatsunori Goto Seitaro Terakura Tetsuya Nishida Hitoshi Kiyoi 《Biology of blood and marrow transplantation》2019,25(3):417-423
Owing to the difficulty in isolating T cells from human biopsy samples, the characteristics of T cells that are infiltratinghuman acute graft-versus-host disease (GVHD) tissues remain largely uninvestigated. In the present study, TCR-β deep sequencing of various GVHD tissue samples and concurrent peripheral blood obtained from transplant recipients was performed in combination with functional assays of tissue-infiltrating T cell clones. The T cell repertoire was more skewed in GVHD tissues than in the peripheral blood. The frequent clonotypes differed from tissue to tissue in the same patient, and the frequent clonotypes in the same tissue differed from patient to patient. Two T cell clones were successfully isolated from GVHD skin of a patient. In a cytotoxicity assay, both Tcell clones lysed patient peripheral blood mononuclear cells, but not donor-derived Epstein-Barr virus-transformed lymphoblastoid cells. Their clonotypes were identical to the most and second most frequent T cell clonotypes in the original GVHD skin and accounted for almost all of the skin-infiltrating T cells. These results suggest that human acute GVHD may result from only a few different alloreactive cytotoxic T cell clones, which differ from tissue to tissue and from patient to patient. The characterization of T cells infiltrating human GVHD tissues should be further investigated. 相似文献
3.
Non‐Hodgkin lymphoma in South East Asia: An analysis of the histopathology,clinical features,and survival from Thailand
下载免费PDF全文
![点击此处可从《Hematological oncology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Tanin Intragumtornchai Udomsak Bunworasate Kitsada Wudhikarn Arnuparp Lekhakula Jakrawadi Julamanee Kanchana Chansung Chittima Sirijerachai Lalita Norasetthada Weerasak Nawarawong Archrob Khuhapinant Noppadol Siritanaratanakul Tontanai Numbenjapon Kannadit Prayongratana Suporn Chuncharunee Pimjai Niparuck Tawatchai Suwanban Nongluk Kanitsap Somchai Wongkhantee Rutchanid Pornvipavee Peerapon Wong Nisa Makruasi Pongsak Wannakrairot Thamathorn Assanasen Sanya Sukpanichnant Paisarn Boonsakan Wasana Kanoksil Charin Ya‐in Kanita Kayasut Winyu Mitranun Naree Warnnissorn 《Hematological oncology》2018,36(1):28-36
4.
Weerapat Owattanapanich Eakkapol Utchariyaprasit Adisak Tantiworawit Ekarat Rattarittamrong Pimjai Niparuck Teeraya Puavilai Jakrawadee Julamanee Pirun Saelue Chantiya Chanswangphuwana Chantana Polprasert Wasithep Limvorapitak Nonglak Kanitsap Chinadol Wanitpongpun Chajchawan Nakhakes Chantarapa Sriswasdi Kannadit Prayongratana 《Clinical Lymphoma, Myeloma & Leukemia》2018,18(12):e509-e514
Background
Elderly patients with acute myeloid leukemia (AML) have a poorer prognosis than younger ones. Several factors contribute to the poor outcomes for this patient group.Patients and Methods
This study investigated the epidemiology, clinical characteristics, treatment, and clinical outcomes of elderly Thai patients with AML. This 3-year, prospective, multicenter study was focused on Thai patients with AML aged over 60 years who were diagnosed between 2014 and 2016.Results
Of 680 patients with AML, 235 elderly patients with AML (34.6%) were identified, with a mean age of 70 ± 8 years. Using a 3-group cytogenetic risk classification (favorable, intermediate, and adverse risk), the proportions of patients in each category were 3.6%, 73.8%, and 22.6%, respectively. The median follow-up time for surviving patients was 846 days. The median overall survival (OS) of the patients was 128.2 days (range, 0-1205 days), with a 1-year OS of 13%. From a multivariate analysis, the significant factors associated with an improved long-term OS were patients with an Eastern Cooperative Oncology Group performance status 0 to 2 and those receiving intensive therapy.Conclusion
Our study confirms the high prevalence of AML in elderly patients with generally poor outcomes. Selected patients with a good performance status and those who received intensive induction treatment could have a long-term survival. 相似文献5.
Kitsada Wudhikarn Udomsak Bunworasate Jakrawadee Julamanee Arnuparp Lekhakula Supachai Ekwattanakit Archrob Khuhapinant Pimjai Niparuck Suporn Chuncharunee Tontanai Numbenjapon Kannadit Prayongratana Nonglak Kanitsap Somchai Wongkhantee Nisa Makruasri Peerapon Wong Lalita Norasetthada Weerasak Nawarawong Chittima Sirijerachai Kanchana Chansung Tawatchai Suwanban Pannee Praditsuktavorn Tanin Intragumtornchai 《Hematological oncology》2019,37(5):578-585
Event free survival at 24 months (EFS24) has been described as a powerful predictor for outcome in several subtypes of B cell lymphoma. However, it was limitedly described in T cell lymphoma. We explored the implication of EFS24 as a predictor marker for peripheral T cell lymphoma (PTCL). We reviewed 293 systemic PTCL patients at 13 nationwide major university hospitals in Thailand from 2007 to 2014. The median event free survival (EFS) and overall survival (OS) of PTCL patients in our cohort was 16.3 and 27.7 months with corresponding 2‐year EFS and 2‐year OS of 45.8% and 51.9%, respectively. A total of 118 patients achieved EFS24 (no events during the first 24 mo). Patients who achieved EFS24 had better OS than patients who did not (2‐y OS 92% vs 18.8%; HR, 0.1; P < .001). The standardized mortality ratio of patients achieving EFS24 was 18.7 (95% CI, 14.6‐22.8). Multivariable analysis demonstrated performance status, histologic subtype, remission status, and EFS24 achievement as independent predictors for OS. Our study affirmed the value of EFS24 as a powerful prognostic factor for PTCL. Further validation in prospective study setting is warranted. 相似文献
1